Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P26038
UPID:
MOES_HUMAN
Alternative names:
Membrane-organizing extension spike protein
Alternative UPACC:
P26038
Background:
Moesin, a member of the Ezrin-radixin-moesin (ERM) family, plays a pivotal role in connecting the actin cytoskeleton to the plasma membrane. This interaction is crucial for the regulation of cell cortex structure and function, including cell shape, membrane transport, and signal transduction. Moesin's activation through phosphorylation on its C-terminal threonine is essential for cytoskeletal rearrangement, impacting both T and B-cells homeostasis and self-tolerance, as well as lymphocyte egress from lymphoid organs.
Therapeutic significance:
Moesin's involvement in Immunodeficiency 50, characterized by recurrent infections, profound lymphopenia, and a poor immune response, highlights its therapeutic potential. Understanding the role of Moesin could open doors to potential therapeutic strategies, offering hope for targeted treatments in primary immunodeficiency disorders.